Ignite Creation Date:
2025-12-25 @ 1:17 AM
Ignite Modification Date:
2026-02-06 @ 11:13 AM
Study NCT ID:
NCT03609593
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-02-07
First Post:
2018-07-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bendamustine/rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Sponsor:
Nicole Lamanna
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
AAAR6357
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None